problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl13251problendo-13251Research ArticleНарушения углеводного обменаCarbohidrates metabolism disturbanciesЭволюция инсулинотерапии: прошлое, настоящее, будущееEvolution of insulin therapy: past, present, futurehttps://orcid.org/0000-0002-1116-3425КуркинД. В.KurkinD. V.

Куркин Денис Владимирович - д.фарм.н., доцент.

Москва

Denis V. Kurkin - doctor of pharmacy, ass. Professor.

Moscow

strannik986@mail.ruhttps://orcid.org/0000-0003-4694-3066БакулинД. А.BakulinD. A.

Бакулин Дмитрий Александрович - к.м.н.

Dmitry A. Bakulin - PhD in medicine.

mbfdoc@gmail.comhttps://orcid.org/0000-0001-6589-5245РобертусА. И.RobertusA. I.

Робертус Александра Игоревна - к.б.н.

Москва

Aleksandra I. Robertus - PhD in biology.

Moscow

spirea@mail.ruhttps://orcid.org/0000-0003-1506-2565КолосовЮ. А.KolosovYu. A.

Колосов Юрий Анатольевич - к.м.н., доцент.

Москва

Yurii A. Kolosov - PhD in medicine, ass. Professor.

Moscow

tronk79@gmail.comhttps://orcid.org/0000-0002-3541-1120КрысановИ. С.KrysanovI. S.

Крысанов Иван Сергеевич - к.фарм.н., доцент.

Москва

Ivan S. Krysanov - PhD in pharmacy, ass. Professor.

Moscow

krysanov-ivan@mail.ruhttps://orcid.org/0000-0002-7119-3546МорковинЕ. И.MorkovinE. I.

Морковин Евгений Игоревич - к.м.н.

Москва

Evgeny I. Morkovin - PhD in medicine.

Moscow

e.i.morkovin@gmail.comhttps://orcid.org/0000-0002-6997-1601СтрыгинА. В.StryginA. V.

Стрыгин Андрей Валерьевич - к.м.н.

Andrei V. Strygin - PhD in medicine.

Volgograd

drumsav@mail.ruhttps://orcid.org/0000-0002-6416-0500ГорбуноваЮ. В.GorbunovaJ. V.

Горбунова Юлия Васильевна - к.фарм.н.

Москва

Julia V. Gorbunova - PhD in pharmacy.

Moscow

yvgorbunova@yandex.ruhttps://orcid.org/0000-0003-2308-0608МакаренкоИ. Е.MakarenkoI. E.

Макаренко Игорь Евгеньевич - к.м.н.

Igor E. Makarenko - PhD in medicine.

igor.makarenko@geropharm.comhttps://orcid.org/0000-0003-4594-6097ДрайР. В.DraiR. V.

Драй Роман Васильевич - к.м.н.

Roman V. Drai - PhD in medicine.

roman.drai@geropharm.comhttps://orcid.org/0000-0003-3767-8475МакароваЕ. В.MakarovaE. V.

Макарова Екатерина Владимировна - к.м.н.

127473, Москва, ул. Делегатская, 20/1; Сантьяго де Компостела

Ekaterina V. Makarova - PhD in medicine.

Delegatskaya str. 20/1, 127473, Moscow, Santiago de Compostela

rue-royal@inbox.ruhttps://orcid.org/0000-0003-0651-3205ПавловаЕ. В.PavlovaE. V.

Павлова Елизавета Валерьевна

Москва

Elizaveta V. Pavlova

lizapavlova1609@yandex.ruhttps://orcid.org/0000-0002-0022-6742КудринР. А.KudrinR. А.

Кудрин Родион Александрович - д.м.н., доцент.

Волгоград

Rodion A. Kudrin - MD, PhD, ass. Professor.

Moscow

rodion.kudrin@gmail.comhttps://orcid.org/0000-0003-4333-322XИвановаО. В.IvanovaO. V.

Иванова Ольга Викторовна - к.фарм.н.

Москва

Olga V. Ivanova - PhD in pharmacy.

Moscow

ovivanova134@mail.ruМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry of A.I. EvdokimovRussian FederationВолгоградский государственный медицинский университетРоссияVolgograd State Medical UniversityRussian FederationМосковский государственный медико-стоматологический университет им. А.И. Евдокимова; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Ю.А.РоссияMoscow State University of Medicine and Dentistry of A.I. Evdokimov; Pirogov Russian National Research Medical UniversityRussian FederationЗАО «Фарм-Холдинг»РоссияPharm-HoldingRussian FederationМосковский государственный медико-стоматологический университет им. А.И. Евдокимова; Университет Сантьяго де КомпостелаИспанияMoscow State University of Medicine and Dentistry of A.I. Evdokimov; Universidad de Santiago de CompostelaSpain20232401202469686101Copyright © Куркин Д.В., Бакулин Д.А., Робертус А.И., Колосов Ю.А., Крысанов И.С., Морковин Е.И., Стрыгин А.В., Горбунова Ю.В., Макаренко И.Е., Драй Р.В., Макарова Е.В., Павлова Е.В., Кудрин Р.А., Иванова О.В., 20242024Куркин Д.В., Бакулин Д.А., Робертус А.И., Колосов Ю.А., Крысанов И.С., Морковин Е.И., Стрыгин А.В., Горбунова Ю.В., Макаренко И.Е., Драй Р.В., Макарова Е.В., Павлова Е.В., Кудрин Р.А., Иванова О.В.Kurkin D.V., Bakulin D.A., Robertus A.I., Kolosov Y.A., Krysanov I.S., Morkovin E.I., Strygin A.V., Gorbunova J.V., Makarenko I.E., Drai R.V., Makarova E.V., Pavlova E.V., Kudrin R.А., Ivanova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/13251

В 2021 г. исполнилось 100 лет со дня открытия инсулина — события, навсегда изменившего жизнь людей с сахарным диабетом. Сегодня пациенты во всем мире ежедневно сталкиваются с чудом инсулинотерапии. Болезнь, от которой в 1920 г. дети и подростки умирали в течение 2 лет, превратилась в болезнь, которую можно контролировать и прожить с ней долгую продуктивную жизнь. За прошедший век великое открытие Бантинга, Беста и Коллипа навсегда изменило мир и спасло миллионы жизней. Данный обзор посвящен истории создания инсулина и его дальнейшего усовершенствования: от момента открытия до наших дней. Рассматриваются различные поколения инсулина: от животных до современных ультракоротких и базальных аналогов. Завершается статья кратким обзором современных направлений развития новых способов доставки и разработки новых молекул инсулина. За последнее столетие инсулинотерапия шагнула далеко вперед, что существенно улучшило качество жизни наших пациентов. Но исследования активно продолжаются, в том числе в области альтернативных способов доставки инсулина, которые являются более удобными для пациента, а также в области разработок «умных» молекул, которые будут обладать глюкозозависимым действием.

2021 marks the 100th anniversary of the discovery of insulin, an event that forever changed the lives of people with diabetes mellitus. At present patients around the world experience the miracle of insulin therapy every day. A disease that used to kill children and teenagers in 2 years in 1920 has become a disease that can be controlled with a possibility to lead a long productive life. Over the past century, the great discovery of Banting, Best and Collip has forever changed the world and saved millions of lives. This review is devoted to the history of the development of insulin and its further improvement: from the moment of discovery to the present days. Various generations of insulin are considered: from animals to modern ultrashort and basal analogues. The article ends with a brief review of current trends in the development of new delivery methods and the development of new insulin molecules. Over the past century, insulin therapy has come a long way, which has significantly improved the quality of life of our patients. But research is actively continuing, including in the field of alternative methods of insulin delivery, which are more convenient for the patient, as well as in the development of «smart» molecules that will have a glucose-dependent effect.

инсулиноткрытиесахарный диабетInsulinopeningdiabetesinsulin therapyРабота поддержана грантом РНФ (проект №20-75-10013)Sorokina Lidia Alexandrovna Leonid Sobolev (1876?1919): At the cradle of insulin discovery Diabetes mellitus 2013 11 103 105 16 1 10.14341/2072-0351-3604Hegele Robert A Maltman Grant M Insulin's centenary: the birth of an idea The Lancet Diabetes & Endocrinology 2020 10 971 977 8 12 10.1016/s2213-8587(20)30337-5Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol. 2018;19(1):31-44. doi: https://doi.org/10.1038/nrm.2017.89Fralick Michael Kesselheim Aaron S. The U.S. Insulin Crisis — Rationing a Lifesaving Medication Discovered in the 1920s New England Journal of Medicine 2019 11 1793 1795 381 19 10.1056/nejmp1909402Cefalu William T. Dawes Daniel E. Gavlak Gina Goldman Dana Herman William H. Van Nuys Karen Powers Alvin C. Taylor Simeon I. Yatvin Alan L. Insulin Access and Affordability Working Group: Conclusions and Recommendations Diabetes Care 2018 05 1299 1311 41 6 10.2337/dci18-0019Owens David R. Insulin Preparations with Prolonged Effect Diabetes Technology & Therapeutics 2011 06 S 5 13 S1 10.1089/dia.2011.0068FAD-approved drugs, Lilly 2021 [Internet]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020563Owens David R. Bolli Geremia B. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications Diabetes, Obesity and Metabolism 2020 01 743 754 22 5 10.1111/dom.13963Heise Tim Linnebjerg Helle Coutant David LaBell Elizabeth Zijlstra Eric Kapitza Christoph Bue‐Valleskey Juliana Zhang Qianyi Dellva Mary Anne Leohr Jennifer Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study Diabetes, Obesity and Metabolism 2020 05 1789 1798 22 10 10.1111/dom.14094de la Peña Amparo Seger Mary Soon Danny Scott Adam J. Reddy Shobha R. Dobbins Michael A. Brown‐Augsburger Patricia Linnebjerg Helle Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL Clinical Pharmacology in Drug Development 2015 08 69 75 5 1 10.1002/cpdd.221Kildegaard Jonas Buckley Stephen T. Nielsen Rasmus H. Povlsen Gro K. Seested Torben Ribel Ulla Olsen Helle B. Ludvigsen Svend Jeppesen Claus B. Refsgaard Hanne H. F. Bendtsen Kristian M. Kristensen Niels R. Hostrup Susanne Sturis Jeppe Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide Pharmaceutical Research 2019 02 36 3 10.1007/s11095-019-2578-7Heise Tim Pieber Thomas R. Danne Thomas Erichsen Lars Haahr Hanne A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes Clinical Pharmacokinetics 2017 02 551 559 56 5 10.1007/s40262-017-0514-8Pal Rimesh Banerjee Mainak Bhadada Sanjay Kumar Glycaemic efficacy and safety of mealtime faster‐acting insulin aspart administered by injection as compared to insulin aspart in people with diabetes mellitus: A meta‐analysis of randomized controlled trials Diabetic Medicine 2021 01 38 3 10.1111/dme.14515Klonoff David C. Evans Mark L. Lane Wendy Kempe Hans‐Peter Renard Eric DeVries J. Hans Graungaard Tina Hyseni Agon Gondolf Theis Battelino Tadej A randomized, multicentre trial evaluating the efficacy and safety of fast‐acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5) Diabetes, Obesity and Metabolism 2018 12 961 967 21 4 10.1111/dom.13610Hirsch Irl B Juneja Rattan Beals John M Antalis Caryl J Wright Eugene E The Evolution of Insulin and How it Informs Therapy and Treatment Choices Endocrine Reviews 2020 05 733 755 41 5 10.1210/endrev/bnaa015Melo Karla F. S. Bahia Luciana R. Pasinato Bruna Porfirio Gustavo J. M. Martimbianco Ana Luiza Riera Rachel Calliari Luis E. P. Minicucci Walter J. Turatti Luiz A. A. Pedrosa Hermelinda C. Schaan Beatriz D. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis Diabetology & Metabolic Syndrome 2019 01 11 1 10.1186/s13098-018-0397-3Nicolucci A, Ceriello A, Di Bartolo P, et al. Rapid-acting insulin analogues versus regular human insulin: A meta-analysis of effects on glycemic control in patients with diabetes. Diabetes Ther. 2020;11(3):573-584. doi: https://doi.org/10.1007/s13300-01900732-wDanne Thomas Matsuhisa Munehide Sussebach Christian Goyeau Harmonie Lauand Felipe Niemoeller Elisabeth Bolli Geremia B. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials Diabetes, Obesity and Metabolism 2020 06 1880 1885 22 10 10.1111/dom.14109Vora Jiten Cariou Bertrand Evans Marc Gross Jorge Luiz Harris Stewart Landstedt-Hallin Lena Mithal Ambrish Rodriguez Martín Rodríguez Meneghini Luigi Clinical use of insulin degludec Diabetes Research and Clinical Practice 2015 04 19 31 109 1 10.1016/j.diabres.2015.04.002Heise Tim Mathieu Chantal Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes Diabetes, Obesity and Metabolism 2016 09 3 12 19 1 10.1111/dom.12782Heise Tim Nørskov Marianne Nosek Leszek Kaplan Kadriye Famulla Susanne Haahr Hanne L. Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes Diabetes, Obesity and Metabolism 2017 03 1032 1039 19 7 10.1111/dom.12938Rosenstock Julio Cheng Alice Ritzel Robert Bosnyak Zsolt Devisme Christine Cali Anna M.G. Sieber Jochen Stella Peter Wang Xiangling Frías Juan P. Roussel Ronan Bolli Geremia B. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial Diabetes Care 2018 08 2147 2154 41 10 10.2337/dc18-0559Philis-Tsimikas Athena Klonoff David C. Khunti Kamlesh Bajaj Harpreet S. Leiter Lawrence A. Hansen Melissa V. Troelsen Lone N. Ladelund Steen Heller Simon Pieber Thomas R. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial Diabetologia 2020 01 698 710 63 4 10.1007/s00125-019-05080-9Kjeldsen Thomas B. Hubálek František Hjørringgaard Claudia U. Tagmose Tina M. Nishimura Erica Stidsen Carsten E. Porsgaard Trine Fledelius Christian Refsgaard Hanne H. F. Gram-Nielsen Sanne Naver Helle Pridal Lone Hoeg-Jensen Thomas Jeppesen Claus Bekker Manfè Valentina Ludvigsen Svend Lautrup-Larsen Inger Madsen Peter Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans Journal of Medicinal Chemistry 2021 05 8942 8950 64 13 10.1021/acs.jmedchem.1c00257Nishimura Erica Pridal Lone Glendorf Tine Hansen Bo Falk Hubálek František Kjeldsen Thomas Kristensen Niels Rode Lützen Anne Lyby Karsten Madsen Peter Pedersen Thomas Åskov Ribel-Madsen Rasmus Stidsen Carsten Enggaard Haahr Hanne Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing BMJ Open Diabetes Research & Care 2021 08 e002301 9 1 10.1136/bmjdrc-2021-002301Rosenstock Julio Bajaj Harpreet S. Janež Andrej Silver Robert Begtrup Kamilla Hansen Melissa V. Jia Ting Goldenberg Ronald Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment New England Journal of Medicine 2020 09 2107 2116 383 22 10.1056/nejmoa2022474KAZDA CHRISTOF M. CHIEN JENNY ZHANG QIANYI CHIGUTSA EMMANUEL LANDSCHULZ WILLIAM WULLENWEBER PAULA HAUPT AXEL FRIAS JUAN P. 192-OR: Glycemic Control with Once-Weekly Basal Insulin Fc (BIF) in Persons with Type 2 Diabetes Mellitus (T2DM) Using Continuous Glucose Monitoring (CGM) in a Phase 2 Study Diabetes 2021 06 70 Supplement_1 10.2337/db21-192-orAndersen Grit Meiffren Grégory Famulla Susanne Heise Tim Ranson Aymeric Seroussi Cyril Eloy Rosy Gaudier Martin Charvet Richard Chan You‐Ping Soula Olivier DeVries J. Hans ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes Diabetes, Obesity and Metabolism 2020 12 961 970 23 4 10.1111/dom.14302Cernea Simona Raz Itamar Insulin Therapy: Future Perspectives American Journal of Therapeutics 2019 09 e121 e132 27 1 10.1097/mjt.0000000000001076McGill Janet B. Weiss Daniel Grant Marshall Jones Marisa C. Kendall David M. Hoogwerf Byron J. Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus Journal of Diabetes 2020 08 164 172 13 2 10.1111/1753-0407.13099Seaquist E. R. Blonde L. McGill J. B. Heller S. R. Kendall D. M. Bumpass J. B. Pompilio F. M. Grant M. L. Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus Diabetic Medicine 2019 12 752 759 37 5 10.1111/dme.14202Gedawy Ahmed Martinez Jorge Al-Salami Hani Dass Crispin R Oral insulin delivery: existing barriers and current counter-strategies Journal of Pharmacy and Pharmacology 2017 11 197 213 70 2 10.1111/jphp.12852Kaur G. Arora M. Ravi Kumar M.N.V. Oral Drug Delivery Technologies—A Decade of Developments Journal of Pharmacology and Experimental Therapeutics 2019 04 529 543 370 3 10.1124/jpet.118.255828Brayden DJ, Hill TA, Fairlie DP, et al. Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches. Adv Drug Deliv Rev. 2020;(157):2-36. doi: https://doi.org/10.1016/j.addr.2020.05.007Eldor Roy Neutel Joel Homer Kenneth Kidron Miriam Efficacy and safety of 28‐day treatment with oral insulin (ORMD‐0801) in patients with type 2 diabetes: A randomized, placebo‐controlled trial Diabetes, Obesity and Metabolism 2021 07 2529 2538 23 11 10.1111/dom.14499Halberg Inge B Lyby Karsten Wassermann Karsten Heise Tim Zijlstra Eric Plum-Mörschel Leona Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial The Lancet Diabetes & Endocrinology 2019 01 179 188 7 3 10.1016/s2213-8587(18)30372-3Wang Aohua Fan Weiwei Yang Tiantian He Shufang Yang Yiwei Yu Miaorong Fan Li Zhu Quanlei Guo Shiyan Zhu Chunliu Gan Yong Liver‐Target and Glucose‐Responsive Polymersomes toward Mimicking Endogenous Insulin Secretion with Improved Hepatic Glucose Utilization Advanced Functional Materials 2020 02 30 13 10.1002/adfm.201910168Abramson Alex Caffarel-Salvador Ester Khang Minsoo Dellal David Silverstein David Gao Yuan Frederiksen Morten Revsgaard Vegge Andreas Hubálek František Water Jorrit J. Friderichsen Anders V. Fels Johannes Kirk Rikke Kaae Cleveland Cody Collins Joy Tamang Siddartha Hayward Alison Landh Tomas Buckley Stephen T. Roxhed Niclas Rahbek Ulrik Langer Robert Traverso Giovanni An ingestible self-orienting system for oral delivery of macromolecules Science 2019 02 611 615 363 6427 10.1126/science.aau2277Klonoff David Bode Bruce Cohen Nathan Penn Marc Geho W. Blair Muchmore Douglas B. Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes Diabetes Care 2019 09 2154 2157 42 11 10.2337/dc19-0152Iacovacci Veronica Tamadon Izadyar Kauffmann Emanuele Federico Pane Stefano Simoni Virginia Marziale Leonardo Aragona Michele Cobuccio Luigi Chiarugi Massimo Dario Paolo Del Prato Stefano Ricotti Leonardo Vistoli Fabio Menciassi Arianna A fully implantable device for intraperitoneal drug delivery refilled by ingestible capsules Science Robotics 2021 08 6 57 10.1126/scirobotics.abh3328Hua Susan Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration Frontiers in Pharmacology 2019 11 10 10.3389/fphar.2019.01328Marciello Marzia Rossi Silvia Caramella Carla Remuñán-López Carmen Freeze-dried cylinders carrying chitosan nanoparticles for vaginal peptide delivery Carbohydrate Polymers 2017 04 43 51 170 10.1016/j.carbpol.2017.04.051Purohit Trusha J. Hanning Sara M. Wu Zimei Advances in rectal drug delivery systems Pharmaceutical Development and Technology 2018 06 942 952 23 10 10.1080/10837450.2018.1484766Xue Jintao Shi Yongli Li Chunyan Xu Xiaojie Xu Shuxin Cao Mingxiang Methylcellulose and polyacrylate binary hydrogels used as rectal suppository to prevent type I diabetes Colloids and Surfaces B: Biointerfaces 2018 08 37 42 172 10.1016/j.colsurfb.2018.08.021Li Qiu Yu Zhang Jia Nan Chen Bo Zhi Wang Qi Lei Guo Xin Dong A solid polymer microneedle patch pretreatment enhances the permeation of drug molecules into the skin RSC Advances 2017 03 15408 15415 7 25 10.1039/c6ra26759aYu Weijiang Jiang Guohua Liu Depeng Li Lei Chen Hua Liu Yongkun Huang Qin Tong Zaizai Yao Juming Kong Xiangdong Fabrication of biodegradable composite microneedles based on calcium sulfate and gelatin for transdermal delivery of insulin Materials Science and Engineering: C 2016 10 725 734 71 10.1016/j.msec.2016.10.063Sugumar Vaisnevee Ang Kuan Ping Alshanon Ahmed F. Sethi Gautam Yong Phelim Voon Chen Looi Chung Yeng Wong Won Fen A Comprehensive Review of the Evolution of Insulin Development and Its Delivery Method Pharmaceutics 2022 07 1406 14 7 10.3390/pharmaceutics14071406Hoeg-Jensen Thomas Review: Glucose-sensitive insulin Molecular Metabolism 2020 10 101107 46 10.1016/j.molmet.2020.101107Dedov I. I. Shestakova M. V. Vikulova O. K. Zheleznyakova A. V. Isakov M. А. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021 Diabetes mellitus 2021 09 204 221 24 3 10.14341/dm12759Jacober S. J. Prince M. J. Beals J. M. Hartman M. L. Qu Y. Linnebjerg H. Garhyan P. Haupt A. Basal insulin peglispro: Overview of a novel long‐acting insulin with reduced peripheral effect resulting in a hepato‐preferential action Diabetes, Obesity and Metabolism 2016 10 3 16 18 S2 10.1111/dom.12744Riddle MC. Lessons from peglispro: IMAGINE how to improve drug development and affordability. Diabetes Care. 2016;39(4):499-501. doi: https://doi.org/10.2337/dc15-2754Mathieu Chantal Martens Pieter-Jan Vangoitsenhoven Roman One hundred years of insulin therapy Nature Reviews Endocrinology 2021 08 715 725 17 12 10.1038/s41574-021-00542-w

The authors declare that there are no conflicts of interest present.